MannKind‘s patent involves drug delivery systems using diketopiperazine carboxylate salts and microparticles, including bioactive agents. The method includes administering dry powder compositions containing a PDE5 inhibitor and a pharmaceutically acceptable salt of a heterocyclic compound to the pulmonary system. GlobalData’s report on MannKind gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights MannKind Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on MannKind, Smart inhalers was a key innovation area identified from patents. MannKind's grant share as of January 2024 was 53%. Grant share is based on the ratio of number of grants to total number of patents.

Dry powder composition for pulmonary delivery of pde5 inhibitor

Source: United States Patent and Trademark Office (USPTO). Credit: MannKind Corp

A recently granted patent (Publication Number: US11872265B2) discloses a method for delivering particles to the pulmonary system through the administration of a dry powder composition by inhalation. The composition includes a phosphodiesterase type 5 (PDE5) inhibitor and a pharmaceutically acceptable salt of a heterocyclic compound. The PDE5 inhibitor can be selected from sildenafil citrate, vardenafil hydrochloride, or tadalafil, with sodium being the preferred cation in the composition.

The method involves preparing the dry powder composition by removing a solvent from a solution containing the PDE5 inhibitor, the salt of the heterocyclic compound, and the cation. Various techniques such as spray drying, evaporation, or lyophilization can be employed for solvent removal. The resulting microparticles of the dry powder are suitable for pulmonary delivery, with specific characteristics such as a rugosity of less than 2 and a diameter less than 5 µm. Additionally, the patent claims methods for the absorption of the PDE5 inhibitor into the circulatory system, emphasizing immediate and sustained absorption when the dry powder composition includes cations formed from sodium and calcium.

To know more about GlobalData’s detailed insights on MannKind, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies